Biolux Technology Revolutionizes Orthodontics with CHF 4M Seed Investment
Share this article
Biolux Technology, a pioneer in light-accelerated orthodontics, has secured CHF 4 million in seed funding from prominent investors, including European venture capital firm redalpine and oral health-focused Revere Partners. This funding marks a pivotal step in Biolux’s mission to revolutionize orthodontic care with its flagship product, OrthoPulse®, and a new smart digital platform.
Accelerating Orthodontics with Light Technology
OrthoPulse® employs patented near-infrared light therapy to significantly accelerate tooth movement, reducing treatment times by up to 50%. This innovative solution addresses critical challenges in orthodontics, including patient compliance and the inefficiencies of lengthy treatments, which often lead to additional refinements and costs. With its exceptionally low failure rate and FDA clearance, OrthoPulse® is already recognized as a game-changer in the field.
The company’s next-generation digital platform will enable real-time treatment monitoring and optimization for both orthodontists and patients, enhancing the overall treatment experience. This aligns with the broader orthodontics market, which is expected to grow from USD 9 billion in 2023 to USD 21 billion by 2030 at a 15% compound annual growth rate.
Strategic Leadership and Growth
Biolux also announced the appointment of Raphael Pascaud as Chairman of the Board. Pascaud brings a wealth of expertise from his leadership roles at industry giants such as DentalMonitoring and Align Technology. His guidance is expected to steer Biolux through its next phase of expansion and innovation.
“Biolux is transforming orthodontics with its cutting-edge technology,” said Marcel Pordes, CEO of Biolux Technology. “This investment enables us to enhance OrthoPulse® further, advance clinical research, and deliver faster, more efficient treatments for patients while supporting orthodontists in providing exceptional care.”
Transforming Orthodontic Care Globally
This funding will drive Biolux’s efforts to scale operations, particularly in the U.S., and position OrthoPulse® as a cornerstone technology in modern orthodontics. With redalpine and Revere Partners backing the initiative, Biolux is poised to expand its market reach and strengthen its leadership in orthodontic innovation.
Daniel Dillinger, Principal at redalpine, expressed confidence in the company’s trajectory: “OrthoPulse®’s patented technology is redefining patient outcomes in orthodontics. We are excited to support Biolux in scaling this transformative solution globally.”
As Biolux continues to innovate, its commitment to improving patient outcomes and orthodontic processes is set to make lasting changes in the field. The company’s pioneering approach is not just about faster treatments; it’s about delivering a smarter, more reliable experience for patients and orthodontists worldwide.
Source text & photo: Press Release